US 11,931,366 B2
Compositions and methods of use thereof for treatment of proteinopathies
Stephen Pak, St. Louis, MO (US); David Perlmutter, St. Louis, MO (US); and Gary Silverman, St. Louis, MO (US)
Assigned to Washington University, St. Louis, MO (US)
Appl. No. 17/048,957
Filed by Washington University, St. Louis, MO (US)
PCT Filed Apr. 19, 2019, PCT No. PCT/US2019/028374
§ 371(c)(1), (2) Date Oct. 19, 2020,
PCT Pub. No. WO2019/204764, PCT Pub. Date Oct. 24, 2019.
Claims priority of provisional application 62/749,854, filed on Oct. 24, 2018.
Claims priority of provisional application 62/660,056, filed on Apr. 19, 2018.
Prior Publication US 2021/0228591 A1, Jul. 29, 2021
Int. Cl. A61K 31/5415 (2006.01); A61K 31/135 (2006.01); A61K 31/138 (2006.01); A61K 31/155 (2006.01); A61K 31/4418 (2006.01); A61K 31/444 (2006.01); A61K 31/4453 (2006.01); A61K 31/505 (2006.01); A61K 31/5355 (2006.01); A61K 31/7135 (2006.01); A61K 45/06 (2006.01); A61P 43/00 (2006.01)
CPC A61K 31/5415 (2013.01) [A61K 31/135 (2013.01); A61K 31/138 (2013.01); A61K 31/155 (2013.01); A61K 31/4418 (2013.01); A61K 31/444 (2013.01); A61K 31/4453 (2013.01); A61K 31/505 (2013.01); A61K 31/5355 (2013.01); A61K 31/7135 (2013.01); A61K 45/06 (2013.01); A61P 43/00 (2018.01)] 7 Claims
 
1. A method for treating a subject having or suspected of having alpha-1-antitrypsin deficiency (ATD), wherein the subject has not developed hepatocellular carcinoma, the method comprising: administering to the subject a therapeutically effective amount of a composition comprising one or more of a proteotoxicity reducing agent selected from Tricyclic antipsychotics, Vasodilators, Antibiotics/Antiseptics, and Aryl piperazines.